CFS

CFS
Name	Chronic fatigue syndrome
Synonyms	Myalgic encephalomyelitis, ME/CFS
Specialty	Neurology, Infectious disease, Immunology

CFS is a disabling condition characterized by persistent, unexplained fatigue accompanied by a constellation of systemic, cognitive, and autonomic symptoms. Patients frequently report post-exertional symptom exacerbation, unrefreshing sleep, and cognitive impairment that impair daily function. Clinical recognition has evolved through contributions from clinicians, patient advocates, and research institutions across North America, Europe, Asia, and Australasia.

Definition and terminology

Terminology for the condition has varied: early labels include benign myalgic encephalomyelitis and "chronic fatigue syndrome" emerged in the 1980s during epidemiologic work by investigators linked to Centers for Disease Control and Prevention, Royal Free Hospital, and specialty clinics in the United States and United Kingdom. Contemporary definitions are informed by consensus statements from panels convened by organizations such as the Institute of Medicine and national health agencies like National Institute for Health and Care Excellence and National Institutes of Health. Diagnostic criteria differ among the Fukuda criteria, the Canadian Consensus Criteria, and staging frameworks used by clinics at academic centers including Johns Hopkins Hospital and Mayo Clinic. Patient advocacy groups such as ME Association and international networks have influenced nomenclature and research priorities.

Causes and pathophysiology

Etiology remains incompletely understood; hypotheses invoke post-infectious processes after exposure to agents studied by investigators at Harvard Medical School, Stanford University, and international laboratories. Reported associations include antecedent viral infections such as Epstein–Barr virus, Coxsackievirus, and Ross River virus, as well as immune activation described in studies from Karolinska Institutet and University of Oxford. Proposed mechanisms include dysregulated innate and adaptive immunity, autonomic nervous system dysfunction examined at Columbia University, mitochondrial bioenergetics defects reported by teams at University of Cambridge, and altered central nervous system signaling identified in imaging studies at Massachusetts General Hospital. Genetic and epigenetic susceptibility loci are under investigation in cohorts coordinated by consortia involving Wellcome Trust and European Molecular Biology Laboratory researchers. No single causal agent has been universally confirmed.

Epidemiology and risk factors

Prevalence estimates vary by case definition and study setting; population surveys by researchers affiliated with University College London, University of California, San Francisco, and national statistics offices suggest prevalence ranges from less than 0.1% to over 1%. Incidence and prevalence differ across regions such as North America, Western Europe, East Asia, and Australia. Risk factors reported in cohort and case–control studies include female sex (noted across studies from Johns Hopkins University and McMaster University), age distribution peaking in mid-adulthood, and preceding infections investigated in outbreaks linked to facilities like the Royal Free Hospital outbreak (1955). Socioeconomic and environmental correlates have been examined by teams at Yale University and University of Toronto; occupational exposures and comorbid psychiatric diagnoses are reported variably across registry studies.

Clinical presentation and diagnosis

Presentation is heterogeneous: patients commonly report profound fatigue, post-exertional symptom exacerbation, sleep disturbance, orthostatic intolerance, and cognitive deficits documented in neuropsychology clinics at UCLA and University of Pennsylvania. Physical examination is often non-specific; autonomic testing from referral centers such as Vanderbilt University Medical Center may reveal orthostatic tachycardia or neurally mediated hypotension. Laboratory testing is directed at excluding alternative diagnoses as recommended by guideline panels at National Institutes of Health and National Institute for Health and Care Excellence. Diagnostic classification relies on symptom-based criteria (for example, the Fukuda criteria, Canadian Consensus Criteria, and recommendations from the Institute of Medicine), supplemented by standardized instruments developed by research groups at RAND Corporation and academic centers.

Management and treatment

There is no universally effective disease-modifying therapy; multidisciplinary care models developed at centers like Mayo Clinic, Cleveland Clinic, and specialty clinics in Scotland emphasize symptom management, activity pacing, sleep optimization, and treatment of comorbidities. Pharmacologic approaches target specific symptoms: analgesics and neuropathic agents used in pain clinics at Stanford University, antidepressants for comorbid mood disorders prescribed following guidelines from American Psychiatric Association, and medications for orthostatic intolerance informed by research at Beth Israel Deaconess Medical Center. Rehabilitation strategies focus on graded activity tailored to avoid post-exertional malaise; behavioral interventions have been evaluated in trials conducted by teams at King's College London and University of Oxford. Emerging investigational therapies include antiviral, immunomodulatory, metabolic, and neuromodulation approaches investigated in randomized and translational studies supported by National Institutes of Health, philanthropic funders, and academic consortia.

Prognosis and outcomes

Outcomes are variable: longitudinal cohort studies from Dartmouth College, University of Melbourne, and University of Birmingham report partial recovery in some patients and persistent disability in others. Functional trajectories depend on factors such as duration of illness at presentation, comorbid conditions, and access to coordinated care; vocational impact has been quantified in health economics studies by groups at London School of Economics and Harvard School of Public Health. Mortality attributable directly to the condition is uncommon, but quality-of-life impairment and loss of productivity constitute substantial burdens documented in national health surveys.

History and research developments

Notable historical milestones include clinical descriptions and outbreak investigations at the Royal Free Hospital in the 1950s, cluster reports in the 1980s prompting surveillance by the Centers for Disease Control and Prevention, publication of the Fukuda criteria in 1994, and subsequent consensus statements by bodies such as the Institute of Medicine (United States) and National Institute for Health and Care Excellence. Research infrastructure has expanded with international collaborations involving European Commission funding, the Solve M.E. initiative, and investigator networks at institutions including Columbia University, University of Oslo, and University of Washington. Contemporary priorities emphasize standardized case definitions, biomarker discovery, randomized therapeutic trials, and patient-centered outcome measures championed by advocacy organizations and academic consortia.

Category:Chronic diseases